Surgery remains the key to progression-free survival in ovarian sex cord-stromal tumours
Two studies presented by the French network TMRG-GINECO provide new insights into the treatment and quality of life of women with this rare cancer
The evolving landscape of rare tumour molecular characterisation
Continued collaboration to identify new molecular targets and treatments can build on existing success
Sinonasal cancer: whole-exome sequencing reveals potential therapeutic targets
Results from a study suggest that some existing inhibitors may benefit all subtypes of these rare malignancies, which currently lack effective treatments
Patients as partners to address unmet needs in sarcoma
However, there are still many obstacles faced by investigators in achieving effective patient involvement in research
Is ATR inhibition a potential new treatment for rare gynaecological cancers?
Ceralasertib, alone or in combination with PARP inhibition, showed signs of clinical efficacy in patients with relapsed ovarian and endometrial clear cell carcinomas (CCC), for whom effective treatment options are currently lacking
What role for real-world evidence in cancer research?
With the growing use of real-world evidence (RWE) to support regulatory approvals of new anti-cancer medicines in Europe and the USA, can this type of research ensure greater inclusion of women, the elderly, diverse ethnic groups, those with rare cancers and other under-represented populations in oncology studies?